Drug profile · INN
daunorubicin
VYXEOS LIPOSOMAL (PREVIOUSLY VYXEOS)
daunorubicin (VYXEOS LIPOSOMAL (PREVIOUSLY VYXEOS)) is a dna topoisomerase ii alpha inhibitor. Associated with Jazz Pharmaceuticals Ireland Limited.
EMA: approved Antineoplastic and immunomodulating agents (L01) L01XY01
Patents linked 0
Pipeline programs 13
News articles 0
Drug details — daunorubicin
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 13
- Data quality
- 0.89
Quick answer
daunorubicin (VYXEOS LIPOSOMAL (PREVIOUSLY VYXEOS)) is a dna topoisomerase ii alpha inhibitor. Associated with Jazz Pharmaceuticals Ireland Limited.
Key facts
INN daunorubicin
Brand VYXEOS LIPOSOMAL (PREVIOUSLY VYXEOS)
Mechanism DNA topoisomerase II alpha inhibitor
Target DNA
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01XY01
Originator Jazz Pharmaceuticals Ireland Limited
Mechanism of action
DNA topoisomerase II alpha inhibitor
Primary target: DNA
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is daunorubicin?
daunorubicin (VYXEOS LIPOSOMAL (PREVIOUSLY VYXEOS)) is a dna topoisomerase ii alpha inhibitor. Associated with Jazz Pharmaceuticals Ireland Limited.
What is the brand name for daunorubicin?
VYXEOS LIPOSOMAL (PREVIOUSLY VYXEOS) is a marketed brand name for daunorubicin. Check FDA Drugs@FDA for the current US label holder and prescribing information.